RTOG 9802: the end of the beginning?

1. RTOG 9802: the end of the beginning? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

2. Low grade glioma Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

3. What are the issues? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

4. R9802 SCHEMA Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

5. Presented at ASCO 2008, published 2012 Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

6. What were the issues? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

7. ASCO 2014: Overall Survival Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

8. Conclusions Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

9. Three trials on adjuvant PCV chemotherapy: the anaplastic OD and LGG trials Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

10. Delayed benefit of chemotherapy Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

11. New WHO grading scheme? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

12. What are the unanswered questions? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

13. What are the unanswered questions? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

14. What are the unanswered questions? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

15. EORTC 22033 on RT vs TMZ in low grade glioma: PFS in relation to 1p status Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

16. Slide 16 Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

17. 2014: the role of chemotherapy established in all diffuse glioma Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

18. Now what? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

19. Slide 19 Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting